{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:53:02Z","timestamp":1789912382956,"version":"4.0.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Smoothened inhibitors (SMOi) have shown activity in Sonic Hedgehog (SHH) medulloblastoma, however this therapeutic class was not developed in children due to severe effects reported on growth. We hereby report long-term follow-up of young patients treated with SMOi for recurrent medulloblastoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical data on response and toxicity from patients treated with vismodegib or sonidegib from 2011 to 2019 for a SHH medulloblastoma were retrospectively reviewed. Methylation analysis and whole exome sequencing were performed whenever possible.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients with a somatic PTCH1 mutation responded to SMOi (6\/8), including 2 prolonged complete responses. One patient was free of disease 8.2 years after treatment. SMOi was challenged again for 3 patients. Two of them had a response, one with SMOi alone, the other one in combination with temozolomide despite previous progression under monotherapy. SMO resistance mutations were found in patients from biopsy at relapse. Combination with temozolomide or surgery plus radiotherapy was associated with very long disease control in 2 patients. The most severe adverse events were myalgia and growth plate fusion with metaphyseal sclerosis. Normal growth velocity was recovered for 1 patient although her final height was below estimated target height.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Targeting SMO in mutated PTCH1 is an interesting strategy for long-term responses. Combination of SMOi with chemotherapy or surgery and local radiotherapy is an appealing strategy to prevent early resistance and diminish SMOi exposure, especially in young patients. Inhibition of SHH pathway causes growth and development impairment but partial recovery of the growth velocity is possible.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdab097","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T19:39:26Z","timestamp":1625686766000},"source":"Crossref","is-referenced-by-count":9,"title":["Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-520X","authenticated-orcid":false,"given":"Victor","family":"Pereira","sequence":"first","affiliation":[{"name":"Department of Pediatric Haematology and Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"},{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Torrejon","sequence":"additional","affiliation":[{"name":"Curie University Institute, CNRS UMR 3347, INSERM U1021, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulanjalee","family":"Kariyawasam","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Diabetology and Gynecology Department, Necker Enfant-Malades University Hospital, AP-HP, Paris, France"},{"name":"Imagine Institute, Inserm U1163, Paris, France"},{"name":"Cochin Institute, Inserm U1016, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Guerrini-Rousseau","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"},{"name":"INSERM, Molecular Predictors and New Targets in Oncology, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ayrault","sequence":"additional","affiliation":[{"name":"Curie University Institute, CNRS UMR 3347, INSERM U1021, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Saint-anne Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnault","family":"Tauzi\u00e8de-Espariat","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Saint-anne Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Puget","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurosurgery, Necker Enfants-Malades University Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bolle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurosurgery, Necker Enfants-Malades University Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Blauwblomme","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurosurgery, Necker Enfants-Malades University Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brugi\u00e8res","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"},{"name":"INSERM, Molecular Predictors and New Targets in Oncology, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-8077","authenticated-orcid":false,"given":"Christelle","family":"Dufour","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"},{"name":"INSERM, Molecular Predictors and New Targets in Oncology, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Oncology, Gustave Roussy Cancer Institute, Paris Saclay University, Villejuif, France"},{"name":"INSERM, Molecular Predictors and New Targets in Oncology, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"7","key":"2021081619412323700_CIT0001","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/1570159X15666171129111324","article-title":"Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights","volume":"16","author":"Khatua","year":"2018","journal-title":"Curr Neuropharmacol."},{"issue":"1","key":"2021081619412323700_CIT0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"2021081619412323700_CIT0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.7842","article-title":"Medulloblastoma: from myth to molecular.","author":"Ramaswamy","year":"2017","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021081619412323700_CIT0004","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell."},{"issue":"5268","key":"2021081619412323700_CIT0005","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science."},{"issue":"7","key":"2021081619412323700_CIT0006","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/ajmg.a.32944","article-title":"Identification of a SUFU germline mutation in a family with Gorlin syndrome","volume":"149A","author":"Pastorino","year":"2009","journal-title":"Am J Med Genet A."},{"issue":"3","key":"2021081619412323700_CIT0007","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.11537","article-title":"Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature","volume":"98","author":"Amlashi","year":"2003","journal-title":"Cancer."},{"issue":"6","key":"2021081619412323700_CIT0008","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.GIM.0000144188.15902.C4","article-title":"Nevoid basal cell carcinoma (Gorlin) syndrome","volume":"6","author":"Gorlin","year":"2004","journal-title":"Genet Med."},{"issue":"10","key":"2021081619412323700_CIT0009","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa042176","article-title":"Treatment of early childhood medulloblastoma by postoperative chemotherapy alone","volume":"352","author":"Rutkowski","year":"2005","journal-title":"N Engl J Med."},{"issue":"33","key":"2021081619412323700_CIT0010","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1200\/JCO.2010.30.2299","article-title":"Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol."},{"issue":"18","key":"2021081619412323700_CIT0011","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.19.03057","article-title":"Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT-2000 and an extended validation cohort","volume":"38","author":"Mynarek","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021081619412323700_CIT0012","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/pbc.26042","article-title":"Clinical, pathological, and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy: molecular characterization of infant MB","volume":"63","author":"Lafay-Cousin","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"2021081619412323700_CIT0013","first-page":";22(12):noaa102","article-title":"Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on \u201cHead Start\u201d III: a multi-institutional, prospective clinical trial","author":"Dhall","year":"2020","journal-title":"Neuro Oncol."},{"issue":"10","key":"2021081619412323700_CIT0014","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-16-2051","article-title":"FDA approval summary: sonidegib for locally advanced basal cell carcinoma","volume":"23","author":"Casey","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2021081619412323700_CIT0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11864-019-0683-9","article-title":"Sonic Hedgehog pathway inhibition in the treatment of advanced basal cell carcinoma","volume":"20","author":"Leavitt","year":"2019","journal-title":"Curr Treat Options Oncol."},{"issue":"12","key":"2021081619412323700_CIT0016","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"N Engl J Med."},{"issue":"22","key":"2021081619412323700_CIT0017","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/1078-0432.CCR-13-1425","article-title":"Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study","volume":"19","author":"Gajjar","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2021081619412323700_CIT0018","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/neuonc\/nox109","article-title":"Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma","volume":"19","author":"Kieran","year":"2017","journal-title":"Neuro Oncol."},{"issue":"41","key":"2021081619412323700_CIT0019","doi-asserted-by":"crossref","first-page":"69295","DOI":"10.18632\/oncotarget.20619","article-title":"Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor","volume":"8","author":"Robinson","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"2021081619412323700_CIT0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-011-0800-8","article-title":"Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups","volume":"121","author":"Ellison","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2021081619412323700_CIT0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mpo.2950240209","article-title":"Recommendations of the Brain Tumor Subcommittee for the reporting of trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology","volume":"24","author":"Gnekow","year":"1995","journal-title":"Med Pediatr Oncol."},{"issue":"20","key":"2021081619412323700_CIT0022","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-17-0381","article-title":"Molecular screening for cancer treatment optimization (MOSCATO-01) in pediatric patients: a single-institutional prospective molecular stratification trial","volume":"23","author":"Harttrampf","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"7697","key":"2021081619412323700_CIT0023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"10","key":"2021081619412323700_CIT0024","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","article-title":"Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays","volume":"30","author":"Aryee","year":"2014","journal-title":"Bioinformatics."},{"issue":"3","key":"2021081619412323700_CIT0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2018.08.002","article-title":"Aberrant ERBB4-SRC signaling as a hallmark of group 4 Mmdulloblastoma revealed by integrative phosphoproteomic profiling","volume":"34","author":"Forget","year":"2018","journal-title":"Cancer Cell."},{"issue":"6","key":"2021081619412323700_CIT0026","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00401-013-1126-5","article-title":"Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays","volume":"125","author":"Hovestadt","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"7409","key":"2021081619412323700_CIT0027","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature11327","article-title":"Subgroup-specific structural variation across 1,000 medulloblastoma genomes","volume":"488","author":"Northcott","year":"2012","journal-title":"Nature."},{"key":"2021081619412323700_CIT0028","first-page":"S0360301620337433","article-title":"Exclusive hyperfractionated radiation therapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the 2 French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups","author":"Carrie","year":"2020","journal-title":"Int J Radiat Oncol."},{"key":"2021081619412323700_CIT0029","first-page":"noaa301","article-title":"Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5","author":"Dufour","year":"2020","journal-title":"Neuro Oncol."},{"issue":"26","key":"2021081619412323700_CIT0030","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","article-title":"Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial","volume":"30","author":"Lannering","year":"2012","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021081619412323700_CIT0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41368-018-0034-x","article-title":"Effect of the sonic hedgehog inhibitor GDC-0449 on an in vitro isogenic cellular model simulating odontogenic keratocysts","volume":"11","author":"Zhai","year":"2019","journal-title":"Int J Oral Sci."},{"issue":"1","key":"2021081619412323700_CIT0032","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-019-03207-x","article-title":"A novel finding of an IDH2 mutation in an interesting adult Sonic Hedgehog mutated medulloblastoma","volume":"144","author":"Fomchenko","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2021081619412323700_CIT0033","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sharpe","year":"2015","journal-title":"Cancer Cell."},{"issue":"5","key":"2021081619412323700_CIT0034","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaad.2014.08.001","article-title":"Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma","volume":"71","author":"Brinkhuizen","year":"2014","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"2021081619412323700_CIT0035","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pbc.20329","article-title":"Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors","volume":"45","author":"Kieffer-Renaux","year":"2005","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2021081619412323700_CIT0036","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med."},{"key":"2021081619412323700_CIT0037","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0773-8","article-title":"Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis","volume":"7","author":"Li","year":"2019","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"2021081619412323700_CIT0038","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2014.02.004","article-title":"Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition","volume":"25","author":"Kool","year":"2014","journal-title":"Cancer Cell."},{"issue":"24","key":"2021081619412323700_CIT0039","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021081619412323700_CIT0040","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"5952","key":"2021081619412323700_CIT0041","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1179386","article-title":"Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma","volume":"326","author":"Yauch","year":"2009","journal-title":"Science."},{"issue":"11","key":"2021081619412323700_CIT0042","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.18632\/oncotarget.23699","article-title":"Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression","volume":"9","author":"Petrirena","year":"2018","journal-title":"Oncotarget."},{"issue":"1","key":"2021081619412323700_CIT0043","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1038\/s41467-019-13657-6","article-title":"scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy","volume":"10","author":"Ocasio","year":"2019","journal-title":"Nat Commun."},{"issue":"1","key":"2021081619412323700_CIT0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","article-title":"Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell."},{"key":"2021081619412323700_CIT0045","doi-asserted-by":"crossref","first-page":"noab087","DOI":"10.1093\/neuonc\/noab087","article-title":"MEVITEM\u2014a Phase I\/II of vismodegib + temozolomide vs temozolomide in patients with recurrent\/refractory medulloblastoma with Sonic Hedgehog pathway activation","author":"Frappaz","year":"2021","journal-title":"Neuro Oncol"},{"issue":"12","key":"2021081619412323700_CIT0046","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1073\/pnas.0504337103","article-title":"Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling","volume":"103","author":"Riob\u00f3","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021081619412323700_CIT0047","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1186\/s12885-018-5066-2","article-title":"A systematic review of non-standard dosing of oral anticancer therapies","volume":"18","author":"Djebbari","year":"2018","journal-title":"BMC Cancer."},{"issue":"3","key":"2021081619412323700_CIT0048","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","volume":"18","author":"Dr\u00e9no","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10","key":"2021081619412323700_CIT0049","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1359\/JBMR.040706","article-title":"Targeted expression of SHH affects chondrocyte differentiation, growth plate organization, and Sox9 expression","volume":"19","author":"Tavella","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2021081619412323700_CIT0050","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1507\/endocrj.45.Suppl_S167","article-title":"Slipped capital femoral epiphysis, Perthes\u2019 disease and scoliosis in children with growth hormone deficiency","volume":"45","author":"Nishi","year":"1998","journal-title":"Endocr J."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdab097\/38878238\/vdab097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab097\/39764502\/vdab097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab097\/39764502\/vdab097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:42:21Z","timestamp":1629142941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdab097\/6316744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdab097","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"vdab097"}}